The Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) is a strategic alliance between LIH and the German Cancer Research Centre (DKFZ) established in 2016 to advance research on oncolytic virus immunotherapy. 

Research projects

The LOVIT research unit mainly focuses on oncolytic rat parvovirus H-1 (H-1PV) which is not pathogenic for humans and possesses oncolytic and oncosuppressive properties.

The research program of LOVIT builds on recent pioneering studies and more specifically on the development ofa first generation of Ad-PV chimeras in which an engineered version of the H-1PV genome was inserted into the Ad5 genome. This  study showed that :

  • The Ad carrier serves as a Trojan horse to efficiently bring the PV-genome into cancer cells,
  • The PV DNA gets excised from the Ad backbone and initiates a genuine PV cycle in an autonomous way.

As a result, the chimeras were shown to be able to specifically infect and kill cancer cells by their cytolytic activity and to produce PV particles able to invade and further propagate into neighboring cancer cells inducing secondary rounds of lytic infection.  

The Ad-PV chimera represents an innovative anticancer agent that can be further improved (e.g. through arming with therapeutic transgenes) and/or combined with other anticancer modalities (e.g. immunotherapy) to enhance antitumour potential.The construction of second generation chimera and the rational design of Ad-PV chimera based combination strategies are the main goals of LOVIT. 

The ambition of the research unit is to produce the necessary proof(s)-of- concept necessary to move most promising therapies from the bench into the clinic.

Featured Publications

Cholestasis induced liver pathology results in dysfunctional immune responses after arenavirus infection.

  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
September 15, 2018
2018 Sep. Sci Rep.8(1):12179.
  • Lang E
  • Pozdeev VI
  • Shinde PV
  • Xu HC
  • Sundaram B
  • Zhuang Y
  • Poschmann G
  • Huang J
  • Stuhler K
  • Pandyra AA
  • Keitel V
  • Haussinger D
  • Lang KS
  • Lang PA.

Inhibition of HIF1alpha-dependent upregulation of Phospho-l-Plastin resensitizes multiple myeloma cells to frontline therapy.

  • Tumor Microenvironment
  • Bioinformatics and Modelling
  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
May 23, 2018
2018 May. Int J Mol Sci.19(6):1551.
  • Bosseler M
  • Marani V
  • Broukou A
  • Lequeux A
  • Kaoma T
  • Schlesser V
  • Francois JH
  • Palissot V
  • Berchem GJ
  • Aouali N
  • Janji B.

Virotherapy Research in Germany: From Engineering to Translation.

  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
October 01, 2017
2017 Oct. Hum Gene Ther.28(10):800-819.
  • Ungerechts G
  • Engeland CE
  • Buchholz CJ
  • Eberle J
  • Fechner H
  • Geletneky K
  • Holm PS
  • Kreppel F
  • Kuhnel F
  • Lang KS
  • Leber MF
  • Marchini A
  • Moehler M
  • Muhlebach MD
  • Rommelaere J
  • Springfeld C
  • Lauer UM
  • Nettelbeck DM.
See all publications


Antonio Marchini


84, rue Val Fleuri
L-1526 Luxembourg
Tel. : +352 26970-856